Fingerprint
Dive into the research topics of 'Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
THOR-2 Cohort 1 Investigators
- University of Sheffield
- Sheffield Teaching Hospitals NHS Foundation Trust
- Peter Maccallum Cancer Centre
- AP-HP
- Université Paris-Saclay
- Faculty of Medicine, University of Tsukuba
- Universitat Autònoma de Barcelona
- University of Southern California
- Sirio Libanes Hospital
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
- East and North Hertfordshire NHS Trust
- University of Hertfordshire
- Janssen Research and Development
- Rush University Medical Center
Research output: Contribution to journal › Article › peer-review
13
Scopus
citations